University of London - London School of Economics and Political Science: High ESMO-MCBS Score Helps Speed Up Cancer Medicine Approvals by HTA Agencies
December 04, 2024
December 04, 2024
LONDON, England, Dec. 4 (TNSres) -- The University of London - London School of Economics and Political Science issued the following news release:
A high ESMO-MCBS score (1), which indicates that a new cancer medicine offers significant clinical benefits, increases the likelihood of a faster, positive decision from Health Technology Assessment agencies (HTAs) such as NICE and the Scottish Medicines Consortium in the UK, according to a new study published in The Lancet Oncology.
A high ESMO-MCBS score (1), which indicates that a new cancer medicine offers significant clinical benefits, increases the likelihood of a faster, positive decision from Health Technology Assessment agencies (HTAs) such as NICE and the Scottish Medicines Consortium in the UK, according to a new study published in The Lancet Oncology.